Causal effects of gut microbiota on diabetic neuropathy: a two-sample Mendelian randomization study
Authors:
Open Access
- 2 August 2024
- journal article
- research article
- Published by Frontiers Media SA in Frontiers in Endocrinology
- Vol. 15, 1388927
Abstract
Objective: Previous observational studies have suggested an association between gut microbiota and diabetic neuropathy (DN). However, confounding factors and reverse causality make the causal relationship between gut microbiota and DN uncertain. We aimed to investigate the interactive causal relationships between the abundance of gut microbiota and DN.Methods: We conducted a Mendelian randomization (MR) analysis to examine the causal relationship between gut microbiota and DN. Genomic data on gut microbiota at the genus level were obtained from the MiBioGen Consortium, including 18,340 individuals of European descent. Data on diabetic polyneuropathy (DPN) were obtained from the FinnGen Consortium, which included 1,048 cases and 374,434 controls, while data on diabetic autonomic neuropathy (DAN) were also obtained from the FinnGen Consortium, including 111 cases and 374,434 controls. Causal effects were primarily estimated using inverse variance weighted (IVW) analysis, supplemented with four validation methods, and additional sensitivity analyses to assess the pleiotropy, heterogeneity, and robustness of instrumental variables.Results: The IVW analysis indicated that Prevotella 9 had a protective effect on DPN (OR = 0.715, 95% CI: 0.521-0.982, P = 0.038), and Bacteroides also showed a protective effect (OR = 0.602, 95% CI: 0.364-0.996, P = 0.048). On the other hand, Ruminococcus 2 had a promoting effect on DPN (OR = 1.449, 95% CI: 1.008-2.083, P = 0.045). Blautia (OR = 0.161, 95% CI: 0.035-0.733, P = 0.018), Clostridium innocuum group (OR = 3.033, 95% CI: 1.379-6.672, P = 0.006), and Howardella (OR = 2.595, 95% CI: 1.074-6.269, P = 0.034) were causally associated with DAN in the IVW analysis, with no evidence of heterogeneity or pleiotropy. Sensitivity analyses showed no significant pleiotropy or heterogeneity.Conclusion: Our study identified a causal relationship between gut microbiota and the increased or decreased risk of diabetic neuropathy. These findings underscore the importance of adopting a comprehensive approach that combines gut microbiota modulation with other therapeutic interventions in the management of diabetic neuropathy.Keywords
This publication has 42 references indexed in Scilit:
- Paeoniflorin ameliorates oxaliplatin-induced peripheral neuropathy via inhibiting neuroinflammation through influence on gut microbiotaEuropean Journal of Pharmacology, 2024
- Tauroursodeoxycholic acid protects Schwann cells from high glucose–induced cytotoxicity by targeting NLRP3 to regulate cell migration and pyroptosisBiotechnology and Applied Biochemistry, 2023
- Gut microbiota modulate distal symmetric polyneuropathy in patients with diabetesCell Metabolism, 2023
- Gut microbiota and pediatric patients with spina bifida and neurogenic bowel dysfunctionChild's Nervous System, 2022
- Dominant gut Prevotella copri in gastrectomised non-obese diabetic Goto–Kakizaki rats improves glucose homeostasis through enhanced FXR signallingDiabetologia, 2020
- Meta‐analysis andMendelianrandomization: A reviewResearch Synthesis Methods, 2019
- Hypoxia-inducible factor 1α protects peripheral sensory neurons from diabetic peripheral neuropathy by suppressing accumulation of reactive oxygen species.Journal of Molecular Medicine, 2018
- A Specific Gut Microbiota Dysbiosis of Type 2 Diabetic Mice Induces GLP-1 Resistance through an Enteric NO-Dependent and Gut-Brain Axis MechanismCell Metabolism, 2017
- Role of the Microbiota in Immunity and InflammationCell, 2014
- Mendelian randomization: Using genes as instruments for making causal inferences in epidemiologyStatistics in Medicine, 2008